GENERAL INFORMATION
The Hellenic Network of Precision Medicine will conduct research with the aim of identifying predisposition to a particular disease and establishing its links to the genetic makeup, the environment and the lifestyle of each individual patient. Conversely, after the onset of a disease, personalized medicine applications and pharmaceutical treatment, based on research findings, can improve outcomes and significantly reduce medical care costs.
Implementation of the Hellenic Network of Precision Medicine flagship action involves the establishment of specialized units for genetic and molecular analysis (next-generation DNA sequencing) and the operation of accredited biobanks (banks collecting clinical data from patients). All data are to be collected and processed on a Web-based computer platform to provide an ever-evolving database, a valuable asset for future research exploitation.
The Hellenic Network of Precision Medicine on Cancer is funded with 5,381,508.28 EUR by SIEMENS, under the settlement agreement between the Hellenic Republic and SIEMENS S.A. It comprises four Precision Medicine Units (PMUs), including two in Attica, one in Thessaloniki and one in Crete. Ten major research and academic organizations working in research and clinical applications in the fields of molecular biology, medicine and computer science are currently partners of the Network.
These are:
- National Center for Scientific Research “Demokritos”
- National Hellenic Research Foundation (NHRF)
- Biomedical Sciences Research Center “Alexander Fleming” (BSRC Alexander Fleming)
- Foundation for Research and Technology-Hellas (FORTH)
- University of Crete School of Medicine
- “Athena” Research & Innovation Center in Information, Communication and Science Technologies
- Hellenic Pasteur Institute (HPI)
- Institute of Applied Bioscience (INAB) / Centre for Research & Technology – Hellas (CERTH)
- Biomedical Research Foundation / Academy of Athens
- National and Kapodistrian University of Athens School of Medicine
